|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
|
30114705 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Most acute promyelocytic leukemia (APL) patients express PML-RARA fusion; in rare cases, RARA is rearranged with partner genes other than PML.
|
29530751 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17)(q22;q21), resulting in the fusion of the promyelocytic leukemia gene at 15q22 with the retinoic acid receptor α at 17q21.
|
30344754 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
|
30289902 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
All-trans retinoic acid and arsenic trioxide treatment has been implemented for promyelocytic leukemia to target the PML-RARα fusion protein.
|
28521962 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Among them, members of the tripartite motif (TRIM) family have emerged as important players endowed with both antiviral effects and modulatory capacity of the innate immune response.TRIM5α and TRIM19 (i.e. promyelocytic leukemia, PML) are among the best-characterized family members; however, in this review we will focus on the potential role of another family member, i.e.
|
29650252 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Subsequent OTI sequences were derived from the observed APL breakpoint between PML and RARA.
|
29447373 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<i>TBL1XR1-RARB</i> as an oncogenic protein exerts effects similar to those of <i>PML-RARA</i>, underpinning the importance of retinoic acid pathway alterations in the pathogenesis of APL.<b>Significance:</b> These findings report a novel and distinct genetic subtype of acute promyelocytic leukemia (APL) by illustrating that the majority of APL without RARA translocations harbor RARB translocations.<i></i>.
|
29921692 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
|
30320491 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Several host gene products, including the nuclear domain 10 (ND10) components PML (promyelocytic leukemia) and Daxx (death domain-associated protein 6), as well as IFI16 (interferon-inducible protein 16), have been shown to restrict herpes simplex virus 1 (HSV-1) replication.
|
29491153 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is a rare leukemia characterized by the balanced reciprocal translocation between the promyelocytic leukemia gene on chromosome 15 and the retinoic acid receptor α (RARα) gene on chromosome 17, and accounts for 10-15% of newly diagnosed acute myeloid leukemia each year.
|
29541170 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein.
|
30026570 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that PML/RARA-mediated downregulation of <i>Irf8</i> transcript levels contributes to the initiation of APL.
|
30266821 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human acute promyelocytic leukemia (APL) cells are characterized by the arrest of differentiation at the promyelocytic stage due to epigenetic perturbations induced by PML/RARα fusion protein (Promyelocytic Leukemia protein - PML/Retinoic Acid Receptor alpha - RARα).
|
29590658 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
PML-RARα perturbs the normal epigenetic setting, which is essential to oncogenic transformation in acute promyelocytic leukemia (APL).
|
29159499 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Of 84 cases (63%) that lacked monocytic differentiation ("myeloid AML"), 40 (48%) demonstrated an acute promyelocytic leukemia-like (APL-like) immunophenotype by flow cytometry, with absence of CD34 and HLA-DR and strong myeloperoxidase expression, in the absence of a PML-RARA translocation.
|
29274134 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
PML(NLS-) was detected in primary APL, but not non-APL cells.
|
28075463 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our findings indicate that FOXC1 is consistently repressed in APL due to hypermethylation and the presence of the PML-RARA rearrangement.
|
29137406 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our current data strongly indicate that PAO has good effects on the mutant PML protein solubility changes, and it may be helpful for improving the therapeutic strategies for arsenic-resistant APL treatments in the near future.
|
28125064 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia.
|
28687976 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
This indicated that PML(NLS‑) may be an effective and novel target for the diagnosis of APL.
|
28849126 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Their expression was decreased after ATO treatment in both NB4 cells (except survivin-2α) and APL patients along with PML-RARα copy number reduction.
|
27770503 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized and driven by the promyelocytic leukemia protein-retinoic acid receptor alpha (PML-RARα) fusion gene.
|
28743050 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Notably, pharmacological inhibition of PML with arsenic trioxide, a PML-degrading agent used to treat promyelocytic leukemia patients, delays tumor growth, impairs TNBC metastasis, and cooperates with chemotherapy by preventing metastatic dissemination.
|
28239645 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the majority of acute promyelocytic leukemia (APL) cases, translocons produce a promyelocytic leukemia protein-retinoic acid receptor α (PML-RARα) fusion gene.
|
28454360 |
2017 |